SK Capital Partners, a private investment firm focused on specialty materials, chemicals and pharmaceuticals, has acquired a majority stake in Seqens, a pharmaceutical services and specialty ingredients company.
With the deal, Seqens entered a combination with SK Capital portfolio company, Wavelength Pharmaceuticals. As a result of the deal, Seqens is a stronger and focused provider in pharmaceutical services and specialty ingredient markets. The firm has a product portfolio including 200 pharmaceutical ingredients, 500 intermediates and key specialty ingredients and chemicals.
“We are excited to have the opportunity to support SEQENS with our deep experience and relationships in the pharmaceutical and specialty ingredients markets,” commented Aaron Davenport, managing director of SK Capital. “SEQENS is well regarded for its recognized know-how, capacity for innovation, global industrial footprint and broad portfolio of products and technologies.”
Piper Sandler together with RBC Capital Markets, LLC and Deutsche Bank acted as M&A advisors to SK Capital on the SEQENS acquisition and Latham & Watkins LLP acted as legal counsel. RBC Capital Markets, LLC acted as financial advisor on the Wavelength contribution into SEQENS and Kirkland & Ellis and Yigal Arnon & Co. acted as legal counsel. Committed debt financing for the transaction was provided by J.P. Morgan, Société Generale, Royal Bank of Canada and Deutsche Bank.